Equities analysts expect Alliqua BioMedical, Inc. (NASDAQ:ALQA) to report sales of $5.08 million for the current quarter, Zacks reports. For the next year, analysts forecast that the company will report earnings of ($0.20) per share, with EPS estimates ranging from ($0.30) to ($0.12). Alliqua BioMedical posted earnings per share of $0.05 during the same quarter last year, which suggests a negative year-over-year growth rate of 440%. The firm is scheduled to issue its next quarterly earnings results on Tuesday, August 8th. Including today's unusual volume, Alliqua BioMedical, Inc.'s stock is performing at -27.17% on the year.
A number of other brokerages have also commented on ALQA. Zacks Investment Research's EPS averages are a mean average based on a survey of analysts that that provide coverage for Alliqua BioMedical.
Alliqua Biomedical (NASDAQ:ALQA) shares traded 16.14% up during most recent session to reach at the closing price of $0.43. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by $0.04. Alliqua BioMedical had a negative return on equity of 75.87% and a negative net margin of 145.99%. For the current year the company's revenue estimates are $20.77 Million compared to low analyst estimates of $20.74 Million and high estimates of $20.8 Million according to 2 number of analysts. However the company reported $0.18 earnings per share for the same quarter during previous year. The company's revenue was up 15.9% on a year-over-year basis. Cowen and Company reissued an "outperform" rating and set a $1.50 price target on shares of Alliqua BioMedical in a research report on Tuesday, April 11th. Zacks Investment Research upgraded Alliqua BioMedical from a hold rating to a buy rating and set a $0.50 price target on the stock in a report on Thursday, March 16th. ValuEngine lowered shares of Alliqua BioMedical from a "sell" rating to a "strong sell" rating in a research report on Friday, June 2nd. They now have a buy rating on the stock. Its book value per share for the most recent quarter is $0.94 while its price to book ratio for the same period is 0.46, as for as the company's cash per share for the most recent quarter is $0.05, however its price to cash per share ratio for the same period is 8.57. Alliqua BioMedical has an average rating of "Hold" and an average price target of $1.19.
Investita da un treno sulla tratta Napoli-Caserta: muore 14enne
Sul posto, in questo momento, si trovano gli uomini dell'arma dei carabinieri ed i sanitari del 118 locale. Si indaga sulle cause del decesso avvenuto all'altezza della stazione ferroviaria di Recale nel casertano.
TRADEMARK VIOLATION WARNING: This piece of content was reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of USA and worldwide copyright law. The legal version of this report can be viewed at https://baseballnewssource.com/markets/alliqua-biomedical-inc-alqa-shares-bought-by-perceptive-advisors-llc-updated-updated/1042517.html. The company had a trading volume of 373,248 shares. Alliqua BioMedical has a 12-month low of $0.32 and a 12-month high of $1.30. The company has market cap of $21.27 million. The stock was acquired at an average cost of $0.40 per share, with a total value of $100,000.00. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. The company was maintained on Friday, November 6 by Chardan Capital Markets. 119,109 shares of the company traded hands. The disclosure for this purchase can be found here. Hedge funds and other institutional investors own 26.19% of the company's stock. Vanguard Group Inc. increased its position in shares of Alliqua BioMedical by 5.3% in the first quarter. Vanguard Group Inc. now owns 449,715 shares of the company's stock worth $227,000 after buying an additional 22,643 shares in the last quarter. Renaissance Technologies LLC now owns 632,800 shares of the company's stock valued at $319,000 after buying an additional 222,400 shares during the period. KCG Holdings Inc. increased its position in shares of Alliqua BioMedical by 777.7% in the first quarter. KCG Holdings Inc. now owns 525,077 shares of the company's stock worth $265,000 after buying an additional 465,256 shares during the last quarter. Sabby Management LLC increased its position in shares of Alliqua BioMedical by 93.7% in the first quarter. Sabby Management LLC now owns 2,131,050 shares of the company's stock worth $1,076,000 after buying an additional 1,030,652 shares in the last quarter. The stock of Alliqua Biomedical Inc (NASDAQ:ALQA) earned "Buy" rating by H.C. Wainwright on Monday, November 2. The Company's businesses include advanced wound care and contract manufacturing.
Alliqua BioMedical, Inc is a provider of advanced wound care solutions.